



Trends in the use of Opioid Agonist Treatment in Victoria, 2013-2022





# Trends in the use of Opioid Agonist Treatment in Victoria, 2013-2022

Kendal Chidwick, Natasa Gisev, Louisa Degenhardt, Michael Farrell & Chrianna Bharat.

Technical report number: 352

Funded by the Australian Government Department of Health and Aged Care and the ASCEND Program.

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation.

All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the National Drug and Alcohol Research Centre, UNSW Sydney, NSW 2052, Australia



### Suggested citation

Chidwick K, Gisev N, Degenhardt L, Farrell M and Bharat C. NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in Victoria, 2013-2022. Sydney: UNSW, 2023. http://doi.org/10.26190/gjpp-py45

### Acknowledgements

We are grateful to IQVIA, and the wholesalers and pharmaceutical manufacturers who provide their sales data to IQVIA, which makes this work possible. NDARC receives core funding from the Australian Government Department of Health & Aged Care. This report was also funded by the ASCEND (Advancing the health of people who use drugs: hepatitis C and drug dependence) NHMRC Program Grant (#1150078).



# Table of Contents

1.	Ex	ecutive Summary6
2.	Ba	ckground & Methods
	2.1.	Background
	2.2.	Aims
	2.3.	Methods 10
3.	Gu	uide to interpretation of results
4.	Fii	ndings16
	4.1.	OAT utilisation by state/territory16
	4.2.	OAT utilisation in Victoria
5.	Di	scussion
6.	Ap	pendices
	6.1.	Mapping to postcodes
	6.2.	Appendix Tables
7.	Re	ferences



# List of Tables

Table 1. Medicines available in the Australian opioid agonist treatment programme1	0
Table 2. Average doses for OAT medicines; data pooled from recent Australian cohort studies1	2

# List of Figures

Figure 1. Number of OAT clients (A), and OAT clients per 10,000 population (B), per month by
Australian state/territory (2013-2022)17
Figure 2. Cumulative number of OAT clients (A) and proportion of total OAT clients (B), per month
by medicine (Victoria, 2013-2022)19
Figure 3. Number of OAT clients by LAI buprenorphine (LAIB) group* (Victoria, 2019-2022)20
Figure 4. Number of OAT clients per month by remoteness (Victoria, 2013-2022)22
Figure 5. Number of OAT clients per month by IRSAD quintile (Victoria, 2013-2022)23
Figure 6. Number of OAT clients per month, by setting (VIC, 2013-2022)25
Figure 7. Number of OAT clients per month by medicine in: community pharmacy (A), hospitals (B),
and other (including prisons) (C) (VIC, 2013-2022)26



## 1. Executive Summary

Opioid agonist treatment (OAT) is one of the main treatments for people with opioid dependence<sup>1</sup>. Involving long-term pharmacotherapy with an opioid agonist or partial agonist, it is well established that OAT reduces non-medical use of opioids, injecting and injecting-related injuries, criminal activity, and overall mortality, particularly overdose mortality<sup>2-5</sup>. The World Health Organization lists both methadone and buprenorphine<sup>6,7</sup>as essential medicines for opioid dependence<sup>8</sup>. In Australia, there are currently four OAT formulations subsidised through the Pharmaceutical Benefit Scheme (PBS), including methadone liquid (PBS listed in 1974), sublingual (SL) buprenorphine (2001), SL buprenorphine-naloxone (2005) and long-acting injectable (LAI) buprenorphine (2019)<sup>9</sup>.

LAI formulations of buprenorphine represent a relatively new addition to OAT in Australia<sup>10</sup>, having been PBS-listed since September 2019. LAI buprenorphine is administered via weekly<sup>11</sup> or monthly<sup>12,13</sup> subcutaneous injections, providing an alternate treatment option that reduces the frequency of dosing visits compared to oral and sublingual OAT alternatives. Several factors may have impacted patterns of OAT medicine use in Victoria (VIC) over the past decade, including the introduction of LAI buprenorphine, the Victorian Government's SafeScript initiative and policy changes in response to the COVID-19 pandemic.

This technical report describes 10-year trends in the sales of OAT medicines in VIC. Aggregate monthly sales were used to estimate the number of OAT clients per month, based on average doses.

#### **Key findings**

- VIC had the third highest level of OAT utilisation after New South Wales and the Australian Capital Territory from 2013 to 2022.
- The estimated number of OAT clients in VIC increased by 54% from 9,227 in January 2013 to 14,169 in December 2022.
- Per capita, VIC saw a 31% increase in rates of use from 16 OAT clients per 10,000 population in January 2013 to 21 per 10,000 in December 2022.
- Patterns of OAT medicines in VIC also changed over this time. There was:
  - o a decline (-4.9%) in clients receiving methadone (2013-2022),



- o an almost 2-fold increase of clients receiving SL buprenorphine (2013-2022), and
- a substantial uptake of LAI buprenorphine following its introduction (35 clients in Sep 2019 to 3,601 clients in Dec 2022).
- Consequently, the distribution of OAT medicines has shifted in VIC:
  - In January 2013, four-fifths (80.3%) of OAT clients received methadone with the remainder receiving SL buprenorphine (19.7%).
  - In December 2022, 49.8% of clients received methadone and 50.2% buprenorphine
    (24.8% SL buprenorphine and 25.4% LAI buprenorphine).
- Across the decade in VIC, trends in the distribution of OAT by remoteness and socioeconomic status remained relatively consistent:
  - 78-80% of OAT in VIC was received in major cities, 16-18% in inner regional areas, and less than 1.0% in remote areas.
  - Over half (55%) of OAT in VIC was delivered in the most advantaged areas (quintiles 4 & 5) and around a fifth (15-20%) in the most disadvantaged areas (quintile 1).
- From 2013 to 2022, the greatest increases in OAT utilisation were observed in inner regional (+71%) areas compared to major cities (+50%).
- The majority (84-96%) of OAT in VIC was accessed through community pharmacies, however access from non-community pharmacy settings increased markedly since 2020.
- Most clients in community pharmacy received methadone whereas, since 2020, most OAT clients attending hospital/outpatient drug and alcohol services and clinics/medical centres received LAI buprenorphine.

#### Conclusions

There has been an increase in OAT utilisation in VIC over the past decade, with around half of clients now receiving buprenorphine and the other half, methadone. Importantly, there has been an increase in access to OAT, overall, and particularly in settings outside of community pharmacy and in inner regional areas, since early 2020 - coinciding with the introduction of LAI buprenorphine, SafeScript and the COVID-19 pandemic. Determining the clinical outcomes of these changes, in terms of benefits, harms and cost-effectiveness, is now a priority.



## 2. Background & Methods

### 2.1. Background

Opioid agonist treatment (OAT) is a first-line treatment for opioid dependence<sup>1</sup>. Involving longterm pharmacotherapy with an opioid agonist, or partial agonist, it is well established that OAT reduces non-medical use of opioids and related harms <sup>3</sup>. For example, there is strong evidence to show that OAT is effective at reducing injecting and injection related injuries, blood-borne viral spread, overdoses and overall mortality<sup>2-5</sup>, as well as improving physical health, social functioning and economic productivity<sup>1</sup>. Methadone and buprenorphine, two of the most common forms of OAT, are both listed by the World Health Organization as essential medicines<sup>8</sup>. In Australia, four formulations of these medicines are approved by the Therapeutics Goods Administration (TGA) and subsidised through the Pharmaceutical Benefit Scheme (PBS) for use as OAT. These include methadone liquid (PBS listed in 1974), sublingual (SL) buprenorphine (2001), SL buprenorphinenaloxone (2005: tablets, 2011: films) and long acting injection (LAI) buprenorphine (September 2019)<sup>9</sup>.

LAI formulations of buprenorphine have recently become available for the treatment of opioid dependence<sup>10</sup>, having been PBS-listed since September 2019. Depending on the formulation, LAI buprenorphine is administered via weekly<sup>11</sup> or monthly<sup>12,13</sup> subcutaneous injections, providing an alternate OAT option to oral methadone and SL buprenorphine, reducing the frequency of dosing visits and increasing flexibility<sup>14,15</sup>. LAI buprenorphine may offer a number of benefits including increased quality of life, employment, and treatment satisfaction<sup>16</sup>, however, the shift to monthly dosing may result in unintended consequences as well<sup>17-19</sup>. In Australia, the roll-out of LAI buprenorphine was stepped up during the COVID-19 pandemic in an effort to reduce face-to-face interactions and the frequency of visits by OAT clients to health services. National interim guidance developed by professional and consumer groups also recommended increasing the number of take-away doses for methadone and SL buprenorphine, greater use of telehealth appointments, and home delivery, including third party collections for clients in quarantine<sup>20</sup>. These recommendations addressed logistical barriers to OAT engagement, including the travel

8



burden associated with attending services<sup>21</sup>. Although their implementation was not mandated, and varied across jurisdictions, understanding the extent to which these changes in guidance impacted access to OAT will help determine the adaptability of the program to support clients.

In 2019 the Victorian Government implemented SafeScript, a real-time prescription monitoring tool, providing prescribers with access to their patients' prescription history for opioids and other high risk medicines.<sup>22</sup> SafeScript automatically collects details of prescriptions issued at a medical clinic or dispensed at a pharmacy in real time. In April 2020 it became mandatory to check SafeScript before prescribing one of the monitored medicines included in the initiative<sup>22</sup>. The potential exists for a new sub-group of people with iatrogenic opioid dependence, identified because of their patterns of opioid prescribing as recorded in SafeScript, to lead to an increase in OAT initiations in Victoria (VIC) from 2019.

Each year, data collected on snapshot day/s by state and territory health departments are compiled to provide a national overview of pharmacotherapies used in the Australian OAT program.<sup>23</sup> Intermittent monitoring such as this, limits a nuanced understanding of how the profile of individual medicines in the OAT program has changed over time and how overall utilisation has changed in different settings (e.g., regional v. remote, community vs. prison). Monthly sales data provide a novel means to examine longitudinal trends of OAT.

This report aims to describe sales of OAT medicines in VIC over time and to consider factors that may have affected patterns of use.

### 2.2. Aims

This report aims to:

- Examine trends in the estimated number of clients on all OAT medicines in VIC between 2013 and 2022, and
- 2. Examine variation in the number of OAT clients by jurisdiction, remoteness, socioeconomic status and setting.



### 2.3. Methods

#### 2.3.1. Study design and time period

This is a descriptive study of trends in the sales of OAT medicines (methadone, SL buprenorphine, SL buprenorphine-naloxone and LAI buprenorphine) in VIC from January 2013 to December 2022.

#### 2.3.2. Data source

Data was provided by IQVIA (iqvia.com) who collect information on sales of medicines to community pharmacies, hospitals, and other providers, including prisons, by pharmaceutical wholesalers and manufacturers. IQVIA declares around 97% coverage of the Australian pharmacy and hospital market<sup>24</sup>. Data on all formulations of OAT medicines sold in VIC between January 2013 and December 2022 (inclusive) were included. Due to the legal requirements for secure storage and monitoring of OAT medicines in pharmacies, the number of packs sold over a 12-month period should closely approximate the number of medicines used by clients in the VIC OAT Program.

#### 2.3.3. Medicines

Available OAT medicines, by formulation and strength, are summarised in Table 1. Formulations of methadone and buprenorphine used solely for the treatment of opioid dependence in Australia were included. In the uncommon event that methadone is used for pain, methadone tablets (which can be crushed) are generally preferred over liquid, in both the community and hospital setting. Methadone liquid 200mL, indicated in Australia for both pain and opioid dependence, was included because most use was assumed to be for opioid dependence. Sales of LAI buprenorphine were disaggregated into five groups relative to strength and injection frequency - weekly low and high strengths, and monthly low, medium and high strengths (see 'LAIB Group' in Table 1). These groups were selected to provide high level trends without identifying individual brands.

Active Ingredient	Form	Brand name	Strength (mg)	LAIB <sup>†</sup> Group	Entry to market <sup>‡</sup>
Methadone	Oral (liquid)	Biodone Forte, Methadone Syrup	5mg / mL	N/A	1974 <sup>25</sup>
Buprenorphine	Sublingual tablet	Subutex	0.4, 2, 8	N/A	2001 <sup>26</sup>

#### Table 1. Medicines available in the Australian opioid agonist treatment programme.





Active Ingredient	Form	Brand name	Strength (mg)	LAIB <sup>+</sup> Group	Entry to market <sup>‡</sup>
Buprenorphine / naloxone	Sublingual tablet / film	Suboxone	2/0.5, 8/2	N/A	2005: Tablets <sup>27</sup> 2011: Films <sup>28</sup>
Buprenorphine	Buprenorphine Long acting injection		8, 16	Weekly LAIB - low	September 2019 <sup>25</sup>
Buprenorphine	Long acting injection	Buvidal weekly	24, 32	Weekly LAIB - high	September 2019 <sup>25</sup>
Buprenorphine	Buprenorphine Long acting injection		64	Monthly LAIB - low	September 2019 <sup>25</sup>
Buprenorphine	Long acting injection	Buvidal monthly	96, 128	Monthly LAIB - med	September 2019 <sup>25</sup>
Buprenorphine	Long-acting injection	Buvidal monthly	160	Monthly LAIB - high	May 2022 <sup>25</sup>
Buprenorphine Long-acting injection		Sublocade	100	Monthly LAIB - low	May 2020 <sup>25</sup>
Buprenorphine	Long-acting injection	Sublocade	300	Monthly LAIB - high	May 2020 <sup>25</sup>

<sup>+</sup>LAIB: Long-acting injection buprenorphine, <sup>‡</sup>Entry to market based on PBS listing as part of the Australian Opioid Dependence Treatment Program

#### 2.3.4. OAT clients per month

Describing OAT utilisation based solely on packs sold does not enable a like-for-like comparison between different medicines. In some cases, one pack may be used to treat one or multiple clients - for example, one pack of LAI buprenorphine treats one client over 28 days, whereas one pack of methadone syrup (1L) may treat several clients. Oral morphine equivalents (OME) were considered less relevant for comparing OAT in a non-analgesia setting and could not be reliably estimated for LAI buprenorphine. For these reasons, the monthly number of packs sold was converted into an estimate of OAT clients per month.

For SL buprenorphine and methadone formulations, OAT clients per month were estimated by summing the total milligrams (mg) contained in the packs sold that month and dividing by the average dose (mg) to treat a single person for 28 days e.g.,

OAT clients per month = 
$$\frac{[mg per pack x Total number of packs sold that month]}{[Average daily dose (mg) for a single person x 28 days]}$$

Average doses were estimated from previous research (see Table 2). For LAI buprenorphine formulations, estimates of clients per month were based on the number of packs (injections) sold. Specifically, one pack of weekly and one pack of monthly LAI buprenorphine were assumed to treat 0.25 and 1 client, respectively, over a 28-day period, aligning with the recommended dosing



schedules<sup>11-13</sup>. A chart review of three Australian OAT providers confirmed these dose estimates aligned with real-world LAI buprenorphine dosing schedules<sup>29</sup>. To account for small fluctuations in sales data, reflecting the ordering behaviour (such as stockpiling) of pharmacies rather than actual fluctuations in OAT client numbers, three-month moving averages are presented.

# Table 2. Average doses for OAT medicines; data pooled from recent Australian cohort studies.

Measure	Methadone li	quid	Sublingual Buprenorphine		
	Pooled estimate (95% CI)	Sources	Pooled estimate (95% Cl)	Sources	
Mean dose (mg/day)	74.06 (69.44, 78.69)	30,31	16.00 (14.39, 17.61)	31	
Median dose (mg/day)	75 (47,75)	31-35	13 (13, 16)	31-36	

Where applicable  $I^2 = 0.0$ .

#### 2.3.5. Geographical information and setting

Monthly OAT utilisation was summarised overall and disaggregated by jurisdiction, remoteness, socioeconomic status, and setting. The Australian jurisdictions includes six states (New South Wales (NSW), Queensland (QLD), South Australia (SA), Tasmania (TAS), VIC, Western Australia (WA), and two territories (Australian Capital Territory (ACT) and the Northern Territory (NT)). Setting refers to the outlet type which purchased the medicines, and includes 'community pharmacy', 'hospital' including outpatient drug and alcohol services, 'aged and community healthcare', 'clinics and medical centres' including general practice, and 'other (including prisons)'. The Australian Bureau of Statistics (ABS) mapping of Postcode 2017 was used to map sales to the Australian Statistical Geography Standard (ASGS) Remoteness Areas 2016 data <sup>37</sup> and to the Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socioeconomic Advantage and Disadvantage (IRSAD) 2016 data<sup>38</sup> (see Appendix 6.1 Mapping to postcode). Australian remoteness categories include 'Major Cities', 'Inner Regional', 'Outer Regional', 'Remote' and 'Very Remote'. IRSAD summarises information about the economic and social conditions of people and households within an area, with lower quintiles indicating relatively greater disadvantage and higher quintiles indicating relatively greater advantage.



#### 2.3.6. Statistical Analysis

Descriptive statistics and data visualisations were used to describe trends over time, and by OAT medicine, jurisdiction, remoteness, socioeconomic status and setting. The estimated number of clients receiving OAT medicines each month, overall and by individual medicines, were evaluated as a count standardised against population size and/or as a proportion (%) of the total number of OAT clients that month. Per capita estimates were based on the estimated residential population at June 30 each year, provided by the ABS<sup>39</sup>, overall and by jurisdiction.

Analyses were conducted using SAS Enterprise Guide 9.4 (SAS Institute Inc., Cary, NC, USA) and Microsoft Excel for Microsoft 365 (Microsoft, Seattle, WA, USA).

#### Ethics approval

Ethics approval was not required as data from IQVIA were received in deidentified aggregated form.



### 3. Guide to interpretation of results

- It is important to acknowledge that the amounts sold do not directly translate to the amounts dispensed or used. For this reason, it was not possible to estimate patterns of use at the client level nor determine the exact number of clients engaged in OAT in each month.
- The approach used in estimating the number of clients receiving OAT per month assumes that real-world OAT doses – and the factors known to influence dose, including disorder severity - have remained stable over time and across different settings. The parameters used to derive these estimates were informed by the literature but have not been validated against population-level data on OAT doses from Australia.
- The estimates assume clients are retained in OAT over the full 28-day interval; where this is not the case, the number of clients accessing OAT at least once a month would be higher.
- This report complements the National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD), which provide a national overview of OAT pharmacotherapies used in Australia on snapshot day/s by state and territory health departments<sup>23</sup>. Where comparisons with NOPSAD show varying trends, these may be explained by differences in client ascertainment and changes in the patterns of OAT retention<sup>40</sup> during the study period.
- Furthermore, IQVIA coverage is not 100%. In particular, there is incomplete capture of sales from VIC settings other than community pharmacy and hospitals in this report (e.g., prisons, clinics and medical centres), leading to an underestimate of the number of clients accessing OAT in these settings.
- If IQVIA coverage has improved over time, this could lead to an underestimate of OAT clients in earlier years of the study and an overestimate of the percentage change between 2013 to 2022.
- As the weekly low dose LAI buprenorphine formulation can be used for top-up or supplemental dosing, inclusion of these formulations may have resulted in a slight overestimate of the number of clients.



- The geographic information provided by IQVIA for non-community pharmacy/hospital settings was less granular (PHN level) so there may be some misclassification of remoteness and socioeconomic categories in these settings.
- It is possible that the socioeconomic status of clients may differ to the socioeconomic status of the area where they obtained their OAT medicine.



# 4. Findings


### 4.1. OAT utilisation by state/territory

Across the decade, Victoria had the second highest number of OAT clients per month of all jurisdictions, after NSW and followed by QLD (Figure 1A). The estimated number of clients receiving OAT each month in VIC increased by 54% from 9,227 clients in January 2013 to 14,169 clients in December 2022 (Figure 1A, Table A1).

After accounting for population size, there was a 31% increase in use in VIC, from 16 OAT clients per 10,000 population in January 2013 to 21 per 10,000 in December 2022 (Figure 1B). By the end of the study (December 2022), the number of OAT clients per capita in VIC was 25% lower than in NSW (21 vs 28 per 10,000 population) and 31% higher than QLD (21 vs 16 per 10,000) (Figure 1B).



Figure 1. Number of OAT clients (A), and OAT clients per 10,000 population (B), per month by Australian state/territory (2013-2022).



ACT: Australian Capital Territory, NSW: New South Wales, NT: Northern Territories, QLD: Queensland, SA: South Australia, TAS: Tasmania, VIC: Victoria, WA: Western Australia



### 4.2. OAT utilisation in Victoria

#### 4.2.1. All OAT medicines

In Victoria, per-capita estimates from 2013 to 2019 ranged between 16 to 19 clients per 10,000 population, before increasing to a range of 20 to 22 clients per 10,000 population, from 2020 onwards (Figure 2B).

Patterns of OAT have changed over time in VIC. Methadone use decreased (-4.9%) from 7,411 clients in 2013 to 7,051 in December 2022 (Figure 2A, Table A1). There was a 2.5-fold increase in the estimated number of clients receiving SL buprenorphine from January 2013 (1,816 clients) to December 2019 (4,465 clients), followed by a 21.3% decrease by December 2022 (3,517 clients). Following its introduction to the market, there was a substantial uptake of LAI buprenorphine from 35 clients in September 2019 to 3,601 clients in December 2022.

Subsequently, the distribution of medicines in the VIC OAT program evolved over time (Figure 2B). In January 2013, four-fifths (80.3%) of the estimated number of OAT clients in VIC received methadone with the remainder receiving SL buprenorphine (19.7%). In December 2022, 49.8% of clients received methadone, 24.8% SL buprenorphine, and 25.4% LAI buprenorphine (Figure 2B, Table A1).


#### 4.2.2. LAI buprenorphine

Since the introduction of LAI buprenorphine, the majority of use was for monthly rather than weekly formulations (Figure 3, Table A2). The formulations in the 'Monthly LAIB – medium' group were used most commonly, until late 2021 when the 'Monthly LAIB – low' group became more frequently used. From September 2019 to December 2022, the uptake of formulations in the 'Monthly LAIB – medium' group increased from 20 to 1,233 clients, 'Monthly LAIB – low' from 9 to 1954 clients and 'Monthly LAIB – high' from <10 clients in March 2020 to 802 clients in December 2022 (Figure 3, Table A2).





Figure 2. Cumulative number of OAT clients (A) and proportion of total OAT clients (B), per month by medicine (Victoria, 2013-2022)




LAI: Long Acting Injection, OAT: Opioid Agonist Treatment, SL: Sublingual





Figure 3. Number of OAT clients by LAI buprenorphine (LAIB) group\* (Victoria, 2019-2022).



\* LAIB groups are defined in Table 1



#### 4.2.1. Remoteness

Over the study period in VIC, trends in the distribution of OAT clients by remoteness remained relatively consistent. Approximately 78-80% of OAT was accessed in major cities, 16-18% in inner regional areas, and less than 1.0% were in remote areas (Table A3). The estimated number of OAT clients increased across all remoteness categories over the decade (Figure 4). From 2013 to 2022, greater increases in OAT utilisation were observed in inner regional (1,511 to 2,586 clients: +71%), areas compared with major cities (7,379 to 11,061 clients: +50%; Figure 4, Table A3).

#### 4.2.2. Socioeconomic status (IRSAD)

Across the decade in VIC, trends in the distribution of OAT utilisation by socioeconomic status remained relatively consistent. Over a half (55%) of the estimated number of OAT clients received OAT in the most advantaged areas (quintiles 4 and 5) and the proportion of clients in the most disadvantaged areas (quintile 1) decreased from around 19% in 2013 to 15% in 2022 (Table A4). From 2013 to 2022, rates of OAT use increased across all IRSAD quintiles, however the greatest increases in OAT use were observed in IRSAD quintiles 3 and 4 (+75%), compared with the most disadvantaged quintile, 1 (+26%) (Figure 5, Table A4).



Figure 4. Number of OAT clients per month by remoteness (Victoria, 2013-2022).







Figure 5. Number of OAT clients per month by IRSAD quintile (Victoria, 2013-2022).



IRSAD: Index of Relative Socioeconomic Advantage and Disadvantage



#### 4.2.3. Setting


In VIC, trends in the distribution of OAT utilisation by setting remained relatively consistent between 2013 and 2019, with changes observed from 2020 to 2022. Very few sales in noncommunity pharmacy settings in VIC were identified in this study. Almost all (around 95%) OAT in VIC was accessed through community pharmacies, until late 2019, when access from noncommunity pharmacy settings increased. The estimated number of clients accessing OAT each month in community pharmacy increased by 38% from 8,700 in January 2013 to 12,886 in December 2020, remaining relatively stable to the end of 2022 (Figure 6). In contrast, the estimated number of clients accessing OAT in clinical and medical centres remained relatively stable from 2013 to 2019/2020, at 0-13 clients per month, before increasing steadily to 860 clients in December 2022 (Figure 6, Table A5). By the end of the study (December 2022) community pharmacies accounted for 85% of OAT in VIC, hospitals 6% and clinics and medical centres 6% (Table A5).

The distribution of medicines in the VIC OAT program varied by setting (Figure 7, Table A6). The majority of clients accessing OAT in community pharmacy each month received methadone whereas, since 2020, the majority of clients accessing OAT in settings other than community pharmacy each month received buprenorphine. By the end of the study (December 2022) in VIC (Figure 7, Table A6):

- 12,033 clients accessed OAT from community pharmacy, of whom 6,822 (56.7%) received methadone, 3,458 (28.7%) SL buprenorphine and 1,753 (14.5%) LAI buprenorphine;
- 914 clients accessed OAT from hospitals (including outpatient drug and alcohol services), of whom 166 (18.2%) received methadone, 58 (6.4%) SL buprenorphine and 689 (75.5%) LAI buprenorphine, and;
- Almost all clients accessing OAT from clinics and medical centre received LAI buprenorphine.




Figure 6. Number of OAT clients per month, by setting (VIC, 2013-2022).





# Figure 7. Number of OAT clients per month by medicine in: community pharmacy (A), hospitals (B), and other (including prisons) (C) (VIC, 2013-2022).





### 5. Discussion

This report used monthly sales data to evaluate trends in the estimated number of clients and the types of OAT medicines used in Victoria between 2013 and 2022. Over the study period, overall utilisation of OAT in VIC increased steadily, with a +31% estimated increase in the per-capita number of OAT clients. The pattern of OAT medicines used in VIC changed over time; in 2013, methadone was most common while in 2022, levels of buprenorphine and methadone were approximately equal. Considerable increases in OAT access were observed, overall, and particularly in settings other than community pharmacies, and in inner regional geographic areas from early 2020 – coinciding with the introduction of LAI buprenorphine, SafeScript and the COVID-19 pandemic.

Importantly this report demonstrates a substantial increase in the use of LAI buprenorphine for OAT in VIC. Between September 2019 (the month LAI buprenorphine was PBS-listed) and December 2022, the estimated number of clients accessing LAI buprenorphine increased substantially, accounting for a quarter of all VIC OAT clients by the end of the study period. By December 2022, most clients in community pharmacy received methadone whereas the majority of clients at hospital/outpatient drug and alcohol services and clinics/medical centres received LAI buprenorphine. This will in part reflect the scale-up of LAI buprenorphine during the COVID-19 pandemic, which was implemented in an effort to reduce exposure to infection, and help adhere with social distancing<sup>20</sup>. At a public hospital in Melbourne, a rapid-access clinic, dedicated to the provision of LAI buprenorphine during the COVID-19 pandemic, was launched that accepted a wide range of referral pathways, at no expense to attendees<sup>41</sup>.

With this significant uptake of LAI buprenorphine, there has been a shift in the distribution of OAT, with equality in the number of clients estimated to be receiving buprenorphine (incl. SL and LAI buprenorphine formulations) and methadone in VIC in the most recent year of data capture. The estimated proportion of all OAT clients receiving buprenorphine increased from a fifth (19.7%) in January 2013 to half (50.2%) of all estimated OAT clients in December 2022. Given the estimated number of clients receiving methadone over the study period decreased only slightly, this finding



aligns with previous reports that buprenorphine is increasingly the medicine most OAT clients initiate on in Australia<sup>40</sup>.

Differences were observed between the findings in this report and the annual summaries from the NOPSAD collection. The client estimates in this report are somewhat lower than those reported in NOPSAD<sup>23</sup>; as the data used in this report has incomplete capture of sales from VIC OAT settings other than community pharmacy and hospitals (e.g., prisons, clinics and medical centres), this was not unexpected. At the beginning of the study period the estimated number of OAT clients in VIC in this report was 33% lower than the figure quoted by NOPSAD (June 2013: 9,351 clients vs 13,961 clients in NOPSAD) and by the end of the study period this difference had reduced to 9% lower (June 2022: 13,733 clients vs 15,153 clients in NOPSAD). Furthermore, 2013 to 2022 data indicates per capita OAT use in VIC increased by +31% in this report (from 16 to 21 OAT clients per 10,000 population) whereas per-capita OAT use remained steady (24 to 23 OAT clients per 10,000 population) according to the NOPSAD collection over the same time period<sup>23</sup>. These differences may be explained by variation in the methods used for client ascertainment, changes in the patterns of OAT retention during the study period<sup>40</sup>, and incomplete capture of sales data (from settings other than community pharmacy and hospital) used in this report. For example, the NOPSAD collection identifies seventeen OAT dosing points at correctional facilities in VIC<sup>23</sup>, however no more than 2% of clients in this report accessed OAT in the 'other (incl. prisons)' setting. NOPSAD collects data on clients receiving OAT on specific day/s per year, whereas the client estimates in this report are based on a conversion of packs sold into clients treated over a month, with the assumption that clients are retained in OAT over the full 28-day interval. As some attrition from OAT is expected this report may underestimate the total number of clients accessing OAT over the month, however, if OAT retention rates have improved over time<sup>40</sup> the potential for this source of underestimation would have diminished over the study time period.

In conclusion, the findings in this report suggest that in VIC, changes in service organisation and delivery during COVID, as well as the introduction of LAI buprenorphine, improved access to OAT for people with opioid dependence, especially in settings other than community pharmacy and



inner regional areas. It is yet to be determined if the increased utilisation is associated with net benefits or harms for people with opioid dependence.



# 6. Appendices

### 6.1. Mapping to postcodes

Data on sales to community pharmacy and hospitals were provided in 'bricks', which are geographic boundaries developed by IQVIA containing clusters of pharmacies, for medicine sales and distribution purposes across Australia. Data on sales to all other settings were provided at the Primary Health Network (PHN) level. Sales bricks and PHNs were mapped to postcodes.

### 6.2. Appendix Tables

#### Table A1. Estimated number and proportion of OAT clients per month (VIC, 2013-2022)

Time period			Met	Methadone SL Bup		Buprenorphine		Total	
	n	Row %	n	Row %	n	Row %	N	Row %	
2013									
January			7411	80.3	1816	19.7	9227	100	
February			7143	83.0	1774	20.6	8607	100	
March			7218	78.0	1811	19.6	9251	100	
April			7192	76.6	1889	20.1	9383	100	
May			7491	75.8	2016	20.4	9886	100	
June			7300	83.1	2051	23.4	8783	100	
July			7426	73.7	2155	21.4	10075	100	
August			7437	71.7	2306	22.2	10369	100	
September			7546	76.1	2574	26.0	9915	100	
October			7583	69.3	2824	25.8	10937	100	
November			7418	72.1	2964	28.8	10295	100	
December			7682	68.0	3160	28.0	11295	100	
2014									
January			7507	73.1	3112	30.3	10268	100	
February			7332	76.0	3073	31.8	9653	100	
March			7190	67.8	2985	28.2	10603	100	
April			7274	66.7	3111	28.5	10898	100	
May			7529	70.0	3223	30.0	10755	100	
June			7431	71.9	3233	31.3	10339	100	
July			7581	66.8	3235	28.5	11354	100	
August			7539	70.9	3235	30.4	10629	100	





Time period	L/ Bupren		Met	hadone	SL Buprenorphine		т	otal
	n	Row %	n	Row %	n	Row %	N	Row %
September			7678	71.0	3252	30.1	10807	100
October			7690	66.4	3315	28.6	11580	100
November			7506	76.2	3239	32.9	9848	100
December			7775	63.5	3446	28.2	12235	100
2015								
January			7423	73.5	3303	32.7	10094	100
February			7346	76.3	3306	34.3	9627	100
March			7105	63.8	3178	28.6	11129	100
April			7178	68.4	3240	30.9	10496	100
May			7402	69.7	3347	31.5	10622	100
June			7273	68.8	3292	31.1	10578	100
July			7400	66.7	3367	30.3	11102	100
August			7381	69.3	3397	31.9	10652	100
September			7358	69.0	3449	32.3	10668	100
October			7340	66.9	3424	31.2	10972	100
November			7236	71.0	3375	33.1	10192	100
December			7441	63.9	3492	30.0	11637	100
2016								
January			7115	74.4	3347	35.0	9556	100
February			7202	68.5	3365	32.0	10508	100
March			6995	64.1	3333	30.5	10921	100
April			7139	70.6	3376	33.4	10114	100
May			7137	66.9	3430	32.2	10665	100
June			7084	67.3	3350	31.8	10522	100
July			7138	67.7	3438	32.6	10543	100
August			7240	65.4	3470	31.4	11063	100
September			7240	69.8	3420	33.0	10373	100
October			7215	68.3	3450	32.7	10559	100
November			7052	67.5	3406	32.6	10440	100
December			7250	61.9	3654	31.2	11712	100
2017								
January			7165	71.0	3581	35.5	10086	100
February			7035	71.6	3506	35.7	9824	100
March			6947	62.5	3395	30.5	11117	100





Time period			Methadone		SL Buprenorphine		Total	
	n	Row %	n	Row %	n	Row %	N	Row %
April			6910	67.8	3467	34.0	10188	100
May			7184	64.4	3634	32.6	11147	100
June			7148	64.0	3685	33.0	11165	100
July			7337	67.0	3752	34.2	10956	100
August			7383	65.1	3768	33.2	11333	100
September			7362	67.5	3704	34.0	10906	100
October			7424	65.5	3764	33.2	11327	100
November			7458	64.7	3796	32.9	11528	100
December			7535	65.6	3912	34.1	11487	100
2018								
January			7489	67.1	3901	35.0	11155	100
February			7181	69.6	3807	36.9	10322	100
March			7304	60.6	3876	32.1	12062	100
April			7150	67.5	3844	36.3	10600	100
May			7476	63.2	4021	34.0	11831	100
June			7309	64.5	3947	34.8	11335	100
July			7544	64.8	4057	34.9	11637	100
August			7554	63.0	4098	34.2	11983	100
September			7321	70.1	4035	38.6	10445	100
October			7366	60.8	4146	34.2	12107	100
November			7256	62.6	4125	35.6	11591	100
December			7591	63.2	4313	35.9	12012	100
2019								
January			7431	65.9	4196	37.2	11278	100
February			7242	67.6	4094	38.2	10719	100
March			7100	62.8	4003	35.4	11313	100
April			7213	61.6	4032	34.4	11706	100
May			7431	60.4	4340	35.3	12294	100
June			7376	66.9	4297	39.0	11020	100
July			7474	60.8	4394	35.8	12289	100
August			7488	62.8	4254	35.7	11915	100
September	35	0.3	7518	66.3	4317	38.1	11336*	100
October	77	0.6	7506	60.4	4336	34.9	12430*	100
November	124	1.0	7459	62.2	4334	36.2	11984	100





Time period			Met	hadone	SL Bup	renorphine	т	otal
	n	Row %	n	Row %	n	Row %	N	Row %
December	191	1.5	7767	60.4	4465	34.7	12852	100
2020								
January	227	2.0	7607	65.6	4310	37.2	11598	100
February	261	2.3	7436	65.2	4257	37.3	11413	100
March	390	2.6	7895	52.5	4395	29.2	15028	100
April	501	4.6	7634	69.8	4323	39.5	10931	100
May	596	4.9	7765	64.4	4309	35.8	12053	100
June	734	5.6	7253	55.3	4046	30.9	13113	100
July	919	6.8	7757	57.4	4220	31.2	13523	100
August	1119	8.4	7990	59.9	4217	31.6	13343	100
September	1240	9.1	8056	59.0	4214	30.8	13661	100
October	1392	9.8	8199	57.4	4169	29.2	14274	100
November	1519	11.3	8171	61.0	4087	30.5	13396	100
December	1652	11.0	8377	55.7	4204	28.0	15029	100
2021								
January	1597	13.1	7916	65.0	4022	33.0	12179	100
February	1605	12.8	7735	61.9	3898	31.2	12505	100
March	1687	11.5	7642	52.2	3779	25.8	14639	100
April	1727	13.6	7764	61.0	3801	29.9	12729	100
May	1844	13.9	7837	59.0	3867	29.1	13275	100
June	1853	13.9	7516	56.4	3743	28.1	13331	100
July	2061	14.8	7588	54.5	3862	27.7	13925	100
August	2249	15.9	7656	54.0	3902	27.5	14167	100
September	2302	17.1	7630	56.7	3918	29.1	13456	100
October	2337	17.3	7557	56.0	3815	28.2	13505	100
November	2398	16.8	7615	53.2	3746	26.2	14314	100
December	2653	17.4	7843	51.3	3872	25.3	15284	100
2022								
January	2902	21.7	7677	57.5	3738	28.0	13352	100
February	2933	23.4	7186	57.3	3604	28.8	12534	100
March	3145	21.4	6939	47.2	3443	23.4	14696	100
April	2988	22.5	6991	52.7	3522	26.5	13273	100
May	3255	23.2	7134	50.9	3606	25.7	14015	100
June	3089	22.2	7080	50.9	3565	25.6	13911	100





Time period	LAI Buprenorphine		Methadone		SL Buprenorphine		Total	
	n	Row %	n	Row %	n	Row %	N	Row %
July	3261	24.2	7000	51.9	3545	26.3	13491	100
August	3242	22.6	7083	49.4	3587	25.0	14336	100
September	3358	23.4	7127	49.7	3573	24.9	14346	100
October	3455	25.4	7126	52.4	3510	25.8	13592	100
November	3568	25.2	7002	49.5	3462	24.5	14157	100
December	3601	24.4	7051	47.8	3517	23.8	14758	100

LAI: Long acting injectable, SL: Sublingual \* Due to the calculation of 3 month moving averages the sum of the number of clients on individual OAT medicines does not tally up to the total number of clients on OAT for the first two months since launch of LAI buprenorphine (i.e., September and October 2019)

#### Table A2. Estimated number of LAI buprenorphine clients per month (VIC, 2019-2022)

		LAI Bı	LAI Buprenorphine group*						
Time period	Monthly LAIB - high	Monthly LAIB - medium	Monthly LAIB - low	Weekly LAIB - high	Weekly LAIB - low				
	n	n	n	n	n				
2019									
September		20	9	<5	<5				
October		54	16	<5	<5				
November		84	31	<5	<5				
December		130	45	8	7				
2020									
January		163	49	9	7				
February	13	190	48	11	9				
March	58	241	80	14	16				
April	94	269	101	19	17				
May	158	264	137	18	19				
June	236	296	170	17	15				
July	290	353	239	19	19				
August	344	428	304	23	21				
September	374	459	350	30	26				
October	401	514	414	31	31				
November	418	577	463	29	32				
December	446	645	505	27	30				
2021									
January	431	611	509	20	26				





		LAI Buprenorphine group*								
Time period Monthly LAIB - hi		Monthly LAIB - medium	Monthly LAIB - low	Weekly LAIB - high	Weekly LAIB - low					
	n	n	n	n	n					
February	430	597	530	21	27					
March	456	613	566	19	34					
April	483	638	553	20	33					
May	540	670	576	24	35					
June	543	674	587	21	28					
July	620	723	657	28	33					
August	662	808	718	29	32					
September	698	810	732	30	32					
October	695	834	748	29	31					
November	600	848	889	29	32					
December	400	1000	1173	41	39					
2022										
January	225	1170	1409	53	46					
February	144	1223	1461	57	49					
March	352	1274	1413	57	49					
April	501	1170	1217	51	48					
May	789	1226	1135	53	52					
June	626	1154	1205	49	54					
July	467	1186	1509	45	54					
August	185	1188	1755	53	62					
September	174	1205	1860	57	62					
October	215	1213	1902	63	62					
November	259	1204	1980	65	59					
December	285	1233	1954	69	61					

\* LAIB groups are defined in Table 1





#### Table A3. Estimated OAT clients per month by remoteness (VIC, 2013-2022)

Time period	Major Cities		Inner Regional		Outer Regional		Remote		Grand Total
	n	Row %	n	Row %	n	Row %	n	Row %	n
2013									
January	7379	80.0	1511	16.4	313	3.4	23	0.3	9227
February	7193	80.7	1417	15.9	281	3.1	26	0.3	8917
March	7299	80.8	1422	15.8	286	3.2	21	0.2	9028
April	7374	81.2	1403	15.4	282	3.1	21	0.2	9080
Мау	7718	81.2	1469	15.5	299	3.1	20	0.2	9506
June	7565	80.9	1468	15.7	293	3.1	25	0.3	9351
July	7717	80.5	1541	16.1	299	3.1	25	0.3	9581
August	7868	80.8	1541	15.8	308	3.2	25	0.3	9743
September	8191	80.9	1577	15.6	328	3.2	24	0.2	10120
October	8405	80.8	1611	15.5	365	3.5	27	0.3	10407
November	8355	80.5	1646	15.9	357	3.4	25	0.2	10382
December	8704	80.3	1719	15.9	392	3.6	28	0.3	10842
2014									
January	8576	80.8	1655	15.6	360	3.4	27	0.3	10619
February	8365	80.4	1636	15.7	377	3.6	27	0.3	10405
March	8217	80.8	1568	15.4	362	3.6	27	0.3	10174
April	8382	80.7	1601	15.4	375	3.6	27	0.3	10384
May	8695	80.9	1642	15.3	385	3.6	30	0.3	10752
June	8604	80.7	1643	15.4	387	3.6	30	0.3	10664
July	8702	80.5	1673	15.5	410	3.8	31	0.3	10816
August	8707	80.8	1635	15.2	400	3.7	31	0.3	10774
September	8783	80.4	1709	15.6	406	3.7	32	0.3	10930
October	8861	80.5	1715	15.6	401	3.6	29	0.3	11005
November	8601	80.0	1706	15.9	410	3.8	28	0.3	10745
December	9015	80.3	1756	15.7	419	3.7	31	0.3	11221
2015									
January	8599	80.2	1685	15.7	408	3.8	33	0.3	10725
February	8570	80.5	1650	15.5	399	3.7	33	0.3	10652
March	8246	80.2	1609	15.6	398	3.9	30	0.3	10283
April	8375	80.4	1617	15.5	398	3.8	28	0.3	10417
May	8614	80.1	1699	15.8	408	3.8	28	0.3	10749
June	8469	80.2	1689	16.0	380	3.6	27	0.3	10565





Time period	Majo	r Cities	Inner	Regional	Outer	Regional	R	emote	Grand Total
	n	Row %	n	Row %	n	Row %	n	Row %	n
July	8606	79.9	1748	16.2	385	3.6	28	0.3	10767
August	8620	80.0	1743	16.2	384	3.6	31	0.3	10777
September	8648	80.0	1721	15.9	408	3.8	31	0.3	10807
October	8625	80.1	1712	15.9	397	3.7	30	0.3	10764
November	8465	79.8	1724	16.2	395	3.7	27	0.3	10610
December	8758	80.1	1740	15.9	405	3.7	30	0.3	10933
2016									
January	8339	79.7	1692	16.2	398	3.8	33	0.3	10461
February	8462	80.1	1670	15.8	403	3.8	32	0.3	10567
March	8237	79.8	1658	16.1	399	3.9	34	0.3	10328
April	8445	80.3	1657	15.8	382	3.6	30	0.3	10514
May	8482	80.3	1664	15.8	389	3.7	32	0.3	10567
June	8383	80.3	1649	15.8	373	3.6	29	0.3	10434
July	8463	80.0	1677	15.9	403	3.8	34	0.3	10577
August	8563	80.0	1700	15.9	412	3.8	35	0.3	10709
September	8517	79.9	1704	16.0	405	3.8	35	0.3	10660
October	8527	80.0	1713	16.1	391	3.7	33	0.3	10665
November	8347	79.8	1695	16.2	379	3.6	36	0.3	10457
December	8730	80.1	1756	16.1	379	3.5	38	0.4	10904
2017									
January	8598	80.0	1735	16.1	376	3.5	37	0.3	10746
February	8417	79.9	1726	16.4	362	3.4	36	0.3	10541
March	8261	79.9	1694	16.4	355	3.4	33	0.3	10342
April	8248	79.5	1727	16.6	366	3.5	35	0.3	10376
May	8585	79.4	1805	16.7	394	3.6	34	0.3	10817
June	8564	79.0	1832	16.9	403	3.7	35	0.3	10833
July	8809	79.4	1843	16.6	403	3.6	34	0.3	11089
August	8880	79.6	1841	16.5	395	3.5	36	0.3	11152
September	8799	79.5	1840	16.6	390	3.5	36	0.3	11065
October	8863	79.2	1879	16.8	409	3.7	38	0.3	11189
November	8904	79.1	1905	16.9	406	3.6	39	0.3	11254
December	9037	78.9	1957	17.1	420	3.7	34	0.3	11447
2018									
January	8994	79.0	1963	17.2	400	3.5	33	0.3	11390
February	8670	78.9	1894	17.2	393	3.6	31	0.3	10988





Time period	Majo	r Cities	Inner	Regional	Outer	Regional	Re	emote	Grand Total
	n	Row %	n	Row %	n	Row %	n	Row %	n
March	8856	79.2	1890	16.9	399	3.6	35	0.3	11180
April	8694	79.1	1865	17.0	401	3.6	34	0.3	10995
May	9105	79.2	1958	17.0	401	3.5	34	0.3	11498
June	8879	78.9	1946	17.3	397	3.5	34	0.3	11255
July	9127	78.7	2020	17.4	417	3.6	37	0.3	11601
August	9146	78.5	2028	17.4	439	3.8	39	0.3	11652
September	8914	78.5	1970	17.4	432	3.8	39	0.3	11355
October	9065	78.7	1990	17.3	419	3.6	37	0.3	11512
November	8935	78.5	1998	17.6	414	3.6	35	0.3	11381
December	9351	78.6	2087	17.5	428	3.6	37	0.3	11903
2019									
January	9111	78.4	2043	17.6	434	3.7	39	0.3	11627
February	8913	78.6	1964	17.3	421	3.7	39	0.3	11336
March	8710	78.4	1948	17.5	412	3.7	34	0.3	11103
April	8812	78.4	1971	17.5	427	3.8	35	0.3	11246
May	9196	78.1	2104	17.9	436	3.7	35	0.3	11771
June	9132	78.2	2071	17.7	437	3.7	34	0.3	11673
July	9266	78.1	2130	18.0	439	3.7	32	0.3	11868
August	9163	78.0	2090	17.8	452	3.9	36	0.3	11742
September	9262	78.2	2104	17.8	445	3.8	37	0.3	11847
October	9317	78.3	2107	17.7	433	3.6	37	0.3	11894
November	9373	78.7	2082	17.5	424	3.6	38	0.3	11917
December	9740	78.4	2191	17.6	450	3.6	41	0.3	12422
2020									
January	9474	78.0	2173	17.9	460	3.8	38	0.3	12145
February	9326	78.0	2139	17.9	453	3.8	37	0.3	11954
March	9988	78.8	2187	17.2	468	3.7	36	0.3	12679
April	9826	78.9	2152	17.3	442	3.5	37	0.3	12457
May	9927	78.3	2234	17.6	472	3.7	37	0.3	12671
June	9314	77.4	2210	18.4	475	3.9	33	0.3	12032
July	10091	78.2	2279	17.7	491	3.8	36	0.3	12896
August	10465	78.5	2334	17.5	490	3.7	37	0.3	13326
September	10647	78.8	2340	17.3	481	3.6	41	0.3	13509
October	10817	78.6	2401	17.4	504	3.7	38	0.3	13759
November	10824	78.6	2402	17.4	512	3.7	39	0.3	13777





Time period	Majo	r Cities	Inner	Regional	Outer	Regional	Re	emote	Grand Total
	n	Row %	n	Row %	n	Row %	n	Row %	n
December	11198	78.7	2460	17.3	536	3.8	40	0.3	14233
2021									
January	10600	78.3	2376	17.6	520	3.8	39	0.3	13535
February	10376	78.4	2330	17.6	495	3.7	36	0.3	13238
March	10199	77.8	2373	18.1	499	3.8	36	0.3	13108
April	10375	78.1	2381	17.9	496	3.7	38	0.3	13291
May	10550	77.9	2442	18.0	515	3.8	40	0.3	13548
June	10229	78.0	2363	18.0	485	3.7	36	0.3	13112
July	10521	77.9	2463	18.2	491	3.6	36	0.3	13510
August	10802	78.2	2487	18.0	486	3.5	33	0.2	13808
September	10823	78.1	2505	18.1	486	3.5	35	0.3	13849
October	10746	78.4	2454	17.9	476	3.5	34	0.2	13709
November	10778	78.3	2472	18.0	476	3.5	32	0.2	13758
December	11282	78.5	2567	17.9	487	3.4	32	0.2	14368
2022									
January	11225	78.4	2559	17.9	500	3.5	33	0.2	14317
February	10692	77.9	2507	18.3	493	3.6	32	0.2	13724
March	10544	77.9	2478	18.3	472	3.5	33	0.2	13527
April	10525	78.0	2482	18.4	465	3.4	30	0.2	13501
May	10947	78.2	2550	18.2	464	3.3	33	0.2	13995
June	10697	77.9	2531	18.4	474	3.5	31	0.2	13733
July	10754	77.9	2562	18.6	461	3.3	29	0.2	13806
August	10874	78.2	2535	18.2	474	3.4	30	0.2	13913
September	11035	78.5	2528	18.0	466	3.3	28	0.2	14058
October	11052	78.4	2529	17.9	479	3.4	31	0.2	14091
November	10977	78.2	2547	18.2	477	3.4	30	0.2	14031
December	11061	78.1	2586	18.2	489	3.5	33	0.2	14169





## Table A4. Estimated OAT clients per month by IRSAD quintile (VIC, 2013-2022)

Time period		most antaged)		2		3		4		most ntaged)	Total
	n	Row %	n	Row %	n	Row %	n	Row %	n	Row %	n
2013											
January	1746	18.9	846	9.2	1536	16.6	2291	24.8	2808	30.4	9227
February	1709	19.2	764	8.6	1482	16.6	2188	24.5	2774	31.1	8917
March	1738	19.2	769	8.5	1499	16.6	2205	24.4	2818	31.2	9028
April	1784	19.6	749	8.2	1481	16.3	2204	24.3	2863	31.5	9080
May	1838	19.3	792	8.3	1555	16.4	2330	24.5	2992	31.5	9506
June	1825	19.5	776	8.3	1525	16.3	2309	24.7	2916	31.2	9351
July	1858	19.4	819	8.5	1576	16.4	2343	24.5	2986	31.2	9581
August	1907	19.6	834	8.6	1605	16.5	2383	24.5	3013	30.9	9743
September	1989	19.7	850	8.4	1677	16.6	2427	24.0	3176	31.4	10120
October	2028	19.5	864	8.3	1760	16.9	2539	24.4	3216	30.9	10407
November	2043	19.7	863	8.3	1747	16.8	2514	24.2	3215	31.0	10382
December	2073	19.1	914	8.4	1838	17.0	2737	25.2	3280	30.3	10842
2014											
January	2030	19.1	877	8.3	1768	16.7	2673	25.2	3272	30.8	10619
February	1978	19.0	871	8.4	1769	17.0	2625	25.2	3161	30.4	10405
March	1988	19.5	847	8.3	1713	16.8	2501	24.6	3125	30.7	10174
April	2034	19.6	865	8.3	1781	17.2	2568	24.7	3136	30.2	10384
May	2118	19.7	908	8.4	1807	16.8	2646	24.6	3273	30.4	10752
June	2068	19.4	908	8.5	1793	16.8	2649	24.8	3245	30.4	10664
July	2129	19.7	944	8.7	1802	16.7	2683	24.8	3259	30.1	10816
August	2116	19.6	903	8.4	1824	16.9	2697	25.0	3234	30.0	10774
September	2145	19.6	934	8.5	1864	17.1	2718	24.9	3269	29.9	10930
October	2128	19.3	939	8.5	1885	17.1	2732	24.8	3321	30.2	11005
November	2078	19.3	930	8.7	1820	16.9	2669	24.8	3247	30.2	10745
December	2197	19.6	969	8.6	1895	16.9	2787	24.8	3373	30.1	11221
2015											
January	2100	19.6	913	8.5	1829	17.1	2665	24.8	3218	30.0	10725
February	2101	19.7	901	8.5	1820	17.1	2639	24.8	3191	30.0	10652
March	1993	19.4	879	8.5	1784	17.3	2514	24.4	3113	30.3	10283
April	2029	19.5	882	8.5	1802	17.3	2563	24.6	3140	30.1	10417
May	2066	19.2	936	8.7	1880	17.5	2618	24.4	3249	30.2	10749
June	2056	19.5	907	8.6	1873	17.7	2589	24.5	3139	29.7	10565





Time		most		2		3		4		most	Total
period	disadv n	antaged) Row %	n	Row %	n	Row %	n	Row %	adva n	ntaged) Row %	n
July	2081	19.3	951	8.8	1890	17.6	2596	24.1	3249	30.2	10767
August	2101	19.5	957	8.9	1897	17.6	2598	24.1	3245	29.9	10777
September	2092	19.4	967	8.9	1912	17.0	2579	23.9	3259	30.2	10807
October	2052	19.4	960	8.9	1912	17.9	2566	23.8	3207	29.8	10764
November	2080	19.6	941	8.9	1928	18.0	2542	24.0	3139	29.6	10610
December	2211	20.2	958	8.8	1905	17.4	2647	24.2	3212	29.4	10933
2016	2211	20.2	550	0.0	1905	17.4	2047	27.2	5212	25.4	10555
January	2078	19.9	926	8.9	1850	17.7	2522	24.1	3085	29.5	10461
February	2083	19.7	924	8.7	1856	17.6	2549	24.1	3155	29.9	10567
March	2040	19.7	921	8.9	1831	17.7	2453	23.8	3083	29.9	10328
April	2057	19.6	914	8.7	1833	17.4	2552	24.3	3159	30.0	10514
May	2070	19.6	921	8.7	1839	17.4	2571	24.3	3165	30.0	10567
June	1981	19.0	904	8.7	1832	17.6	2579	24.7	3137	30.1	10434
July	2067	19.5	941	8.9	1865	17.6	2572	24.3	3132	29.6	10577
August	2080	19.4	950	8.9	1913	17.9	2568	24.0	3199	29.9	10709
September	2089	19.6	946	8.9	1902	17.8	2550	23.9	3172	29.8	10660
October	2052	19.2	943	8.8	1901	17.8	2559	24.0	3210	30.1	10665
November	2029	19.4	948	9.1	1850	17.7	2522	24.1	3109	29.7	10457
December	2111	19.4	971	8.9	1913	17.5	2622	24.0	3287	30.1	10904
2017											
January	2093	19.5	961	8.9	1882	17.5	2593	24.1	3217	29.9	10746
February	2010	19.1	940	8.9	1850	17.5	2567	24.3	3175	30.1	10541
March	1947	18.8	924	8.9	1814	17.5	2529	24.5	3128	30.2	10342
April	1964	18.9	934	9.0	1815	17.5	2511	24.2	3151	30.4	10376
May	2066	19.1	976	9.0	1900	17.6	2604	24.1	3272	30.2	10817
June	2064	19.1	983	9.1	1931	17.8	2606	24.1	3250	30.0	10833
July	2111	19.0	979	8.8	1996	18.0	2674	24.1	3330	30.0	11089
August	2147	19.3	977	8.8	2000	17.9	2700	24.2	3328	29.8	11152
September	2120	19.2	976	8.8	1980	17.9	2689	24.3	3300	29.8	11065
October	2169	19.4	997	8.9	2025	18.1	2713	24.3	3285	29.4	11189
November	2149	19.1	1003	8.9	2040	18.1	2753	24.5	3309	29.4	11254
December	2189	19.1	1031	9.0	2104	18.4	2798	24.4	3325	29.0	11447
2018											
January	2128	18.7	1037	9.1	2104	18.5	2791	24.5	3329	29.2	11390
February	2056	18.7	995	9.1	2043	18.6	2680	24.4	3214	29.2	10988





Time period		most antaged)		2		3		4		most ntaged)	Total
	n	Row %	n	Row %	n	Row %	n	Row %	n	Row %	n
March	2098	18.8	1007	9.0	2093	18.7	2713	24.3	3269	29.2	11180
April	2065	18.8	995	9.1	2028	18.4	2708	24.6	3198	29.1	10995
May	2134	18.6	1050	9.1	2137	18.6	2843	24.7	3333	29.0	11498
June	2076	18.4	1035	9.2	2063	18.3	2827	25.1	3254	28.9	11255
July	2145	18.5	1074	9.3	2152	18.6	2872	24.8	3357	28.9	11601
August	2169	18.6	1084	9.3	2170	18.6	2874	24.7	3354	28.8	11652
September	2103	18.5	1079	9.5	2081	18.3	2789	24.6	3303	29.1	11355
October	2132	18.5	1080	9.4	2114	18.4	2838	24.7	3347	29.1	11512
November	2117	18.6	1091	9.6	2058	18.1	2782	24.4	3333	29.3	11381
December	2223	18.7	1119	9.4	2202	18.5	2886	24.2	3473	29.2	11903
2019											
January	2187	18.8	1116	9.6	2146	18.5	2798	24.1	3380	29.1	11627
February	2114	18.7	1073	9.5	2103	18.6	2736	24.1	3310	29.2	11336
March	2067	18.6	1076	9.7	2064	18.6	2659	23.9	3236	29.1	11103
April	2067	18.4	1091	9.7	2066	18.4	2719	24.2	3304	29.4	11246
May	2175	18.5	1138	9.7	2221	18.9	2824	24.0	3413	29.0	11771
June	2172	18.6	1105	9.5	2203	18.9	2837	24.3	3356	28.7	11673
July	2158	18.2	1135	9.6	2269	19.1	2914	24.6	3392	28.6	11868
August	2119	18.0	1127	9.6	2238	19.1	2898	24.7	3361	28.6	11742
September	2119	17.9	1139	9.6	2247	19.0	2931	24.7	3411	28.8	11847
October	2122	17.8	1125	9.5	2296	19.3	2910	24.5	3441	28.9	11894
November	2159	18.1	1112	9.3	2256	18.9	2960	24.8	3429	28.8	11917
December	2186	17.6	1171	9.4	2401	19.3	3087	24.8	3578	28.8	12422
2020											
January	2134	17.6	1165	9.6	2312	19.0	3042	25.1	3492	28.8	12145
February	2037	17.0	1167	9.8	2288	19.1	2986	25.0	3475	29.1	11954
March	2150	17.0	1203	9.5	2445	19.3	3158	24.9	3724	29.4	12679
April	2139	17.2	1195	9.6	2396	19.2	3123	25.1	3604	28.9	12457
May	2171	17.1	1235	9.7	2449	19.3	3159	24.9	3657	28.9	12671
June	2113	17.6	1225	10.2	2289	19.0	3022	25.1	3383	28.1	12032
July	2220	17.2	1272	9.9	2467	19.1	3254	25.2	3684	28.6	12896
August	2290	17.2	1306	9.8	2539	19.1	3385	25.4	3806	28.6	13326
September	2277	16.9	1310	9.7	2604	19.3	3448	25.5	3871	28.7	13509
October	2328	16.9	1327	9.6	2658	19.3	3538	25.7	3909	28.4	13759
November	2311	16.8	1335	9.7	2652	19.3	3642	26.4	3836	27.8	13777





October225916.513239.7258918.9373927.3379827.713709November227316.513319.7261219.0377327.4377027.41378December230516.013889.7277419.3398327.7391727.3143682022111111111111January224115.713929.7282219.7399027.9387127.014317February217415.8136810.0270419.7378027.5369826.913527March215315.913419.9262719.4376727.9363926.913527March215315.913419.9262719.4376727.9363926.913527March215315.913419.9262719.4376727.9363926.913527Marth218715.613709.827.1819.4376727.9363926.913527June218715.613709.827.1819.4376728.4374526.813955June218615.713479.826.8519.6387328.236.126.71373June218615.51348<	Time period		most antaged)		2		3		4		most ntaged)	Total
2021Image of the stateImage of the state<		n	Row %	n	Row %	n	Row %	n	Row %	n	Row %	n
January226716.813319.8258219.1360226.6375327.71333February224316.912779.6255219.3344926.1370728.013238March224417.112879.6255219.3344026.1370728.01318April223016.812949.7256919.3353526.6366327.61319May225416.613299.8261119.3360826.6378827.61314June217616.612729.7251419.2352726.9362227.61314Juny228316.513149.7261119.3358926.6371827.51350August228316.513369.7261719.2378827.4378827.61389September226516.413439.7265719.2378627.4378927.41379November223916.513339.7262119.037327.4379027.41379November223916.513319.7261219.037327.4379127.41378December230516.013889.727.419.4378927.7381427.41374January24115.8 <td>December</td> <td>2377</td> <td>16.7</td> <td>1372</td> <td>9.6</td> <td>2727</td> <td>19.2</td> <td>3783</td> <td>26.6</td> <td>3973</td> <td>27.9</td> <td>14233</td>	December	2377	16.7	1372	9.6	2727	19.2	3783	26.6	3973	27.9	14233
February224316.912779.6255219.3345926.1370728.013238March224417.112879.8256619.3344026.2360027.513108April223016.812949.7256919.3353526.6363327.613291May225416.613299.8261919.3350826.6373827.613121June217616.612729.7251419.2352726.637827.613121July22816.513369.7261119.3358926.637827.713121July228316.513369.7265019.2378127.4378027.71388September226516.413439.7258918.9373927.3378927.71379Norember227316.513239.7258918.9373927.4370727.41378December230516.013889.727.419.0373327.4370727.41378January224115.713899.726219.7398327.7391727.31431January214915.8136926.719.417.417.417.417.417.4January214915.91349 </td <td>2021</td> <td></td>	2021											
March April224417.112879.8253619.3344026.2360027.513108April223016.812949.7266919.3353526.6363327.613291May225416.613299.8261919.3360826.637.827.61312Jun217616.612729.7251419.2352726.9362227.61312July228316.513369.7265019.2378427.4378827.51380Aquett228316.513369.7265019.2378627.2381927.61389September226516.413439.7265719.2378627.3378827.71380September226516.413439.7265719.2378527.4378927.61389October229316.513239.7262916.9373927.4379927.61379November220316.513319.7262919.0373927.7391727.41378December230516.013889.727.419.527.7391727.41374Januer217415.8136910.027.419.7390927.7363926.91374Januer15.71369	January	2267	16.8	1331	9.8	2582	19.1	3602	26.6	3753	27.7	13535
April223016.8.12949.7.256919.3.353526.6.363327.6.13291May225416.6.13299.8.261919.3.360826.6.373827.6.13548June217616.6.12729.7.251419.2.352726.9.362227.6.1311July227816.9.13149.7.261119.3.358926.6.37.827.5.1350Augut228316.5.13369.7.265719.2.37.6.27.2.38.927.7.1389October225916.5.13239.7.258918.9.37.9.27.3.37.8.27.7.1379Norember227316.5.13319.7.261219.0.37.3.27.4.37.0.27.4.1379Norember227316.5.13319.7.261219.0.37.3.27.4.37.0.27.4.1379Norember220316.5.13319.7.27.419.3.39.8.27.7.39.1.27.3.14368202016.5.16.6.13889.7.27.419.5.37.8.27.5.36.9.27.4.1371February217415.5.13499.7.262719.4.376727.9.36.9.26.9.1372April215615.7.13419.9.26.719.4.376727.9.36.9.	February	2243	16.9	1277	9.6	2552	19.3	3459	26.1	3707	28.0	13238
May225416.613299.8261919.3360826.6373827.61348June217616.612729.7251419.2352726.9362227.613112July227816.913149.7261119.3358926.6371827.513510August228316.513369.7265019.2378127.4375827.213808September226516.413439.7265719.2376027.3378827.71389October225916.513239.7258918.9373927.3378827.71379November227316.513319.7258918.9373927.4370027.41378December230516.013889.727.419.3398327.7391727.3143682022111.513319.7282219.7398027.9387127.014378January224115.713929.7282219.7399027.9387127.014317February217415.8136810.0270419.7378027.9369326.91324March215315.913419.9262719.4376427.9363926.91351Juny2164 <t< td=""><td>March</td><td>2244</td><td>17.1</td><td>1287</td><td>9.8</td><td>2536</td><td>19.3</td><td>3440</td><td>26.2</td><td>3600</td><td>27.5</td><td>13108</td></t<>	March	2244	17.1	1287	9.8	2536	19.3	3440	26.2	3600	27.5	13108
June217616.612729.7251419.2352726.9362227.613112July227816.913149.7261119.3358926.6371827.51350August228316.513369.7265019.2378127.4378027.61389September226516.413439.7258918.9373927.3379827.71379Notember225916.513239.7258918.9373927.4379027.41379Notember223716.513319.7261219.0373327.4379127.41378December230516.013889.7277419.3398327.7391727.31436820221115.713929.7282219.7399027.9387127.014378January224115.713929.7282219.7399027.9363926.913274January217415.8136810.0270419.7378027.5369826.913274January214315.913419.9262719.4378027.9363926.913274January214515.8136820.121.613.827.114.928.927.936.926.913274 </td <td>April</td> <td>2230</td> <td>16.8</td> <td>1294</td> <td>9.7</td> <td>2569</td> <td>19.3</td> <td>3535</td> <td>26.6</td> <td>3663</td> <td>27.6</td> <td>13291</td>	April	2230	16.8	1294	9.7	2569	19.3	3535	26.6	3663	27.6	13291
July227816.913149.7261119.3358926.6371827.513510August228316.513369.7265019.2378127.4375827.23819September226516.413439.7258919.2376627.3379827.71379October225916.513239.7258918.9373927.3379827.71379November227316.513319.7261219.0373327.4370927.41378December230516.013889.7277419.3398327.7391727.31436202210.16.513849.727.719.7391727.3391727.31437January224115.713929.727.719.3398327.7391727.91437January217415.813689.7282219.7399027.9387127.01437January214315.913499.9262719.4378027.9369326.91327January214415.813689.9282619.4376727.9363926.91327January214515.913499.926.719.4376727.9363927.01351January2155	May	2254	16.6	1329	9.8	2619	19.3	3608	26.6	3738	27.6	13548
August228316.513369.7265019.2378127.4375827.213808September226516.413439.7265719.2376627.2381927.613849October225916.513239.7258918.9373927.3379827.713709November227316.513319.7261219.0377327.4370027.413758December230516.013889.727.419.3398327.7391727.31436820221113799.7282219.7398327.7387127.014379January224115.713929.7282219.7399027.9387127.014317February217415.8136810.0270419.7378027.5369826.913274March215315.913419.9262719.4376727.9363926.913527April215616.013389.9258619.2378228.0363927.013501March215615.713479.827.119.4397428.4374526.813995June215615.713489.827.019.6387328.2367126.71373June215615	June	2176	16.6	1272	9.7	2514	19.2	3527	26.9	3622	27.6	13112
September226516.413439.7265719.2376627.2381927.613849October225916.513239.7258918.9373927.3379827.713709November227316.513319.7261219.0377327.4377027.413758December230516.013889.7277419.3398327.7391727.3143682022111	July	2278	16.9	1314	9.7	2611	19.3	3589	26.6	3718	27.5	13510
October225916.513239.7258918.9373927.3379827.713709November227316.513319.7261219.0377327.4370027.413758December230516.013889.7277419.3398327.7391727.3143682022Image: Constraint of the state of the stat	August	2283	16.5	1336	9.7	2650	19.2	3781	27.4	3758	27.2	13808
November227316.513319.7261219.0377327.4377027.41378December230516.013889.7277419.3398327.7391727.314368202211111111111January224115.713929.7282219.7399027.9387127.014317February217415.8136810.0270419.7378027.5369826.913724March215315.913419.9262719.4376727.9363926.913527April215616.013389.9268619.2378228.0363926.913527April218715.613709.827.1819.4376228.0363926.91350June218615.713479.8268519.4376728.4376326.51373June218615.513489.8270119.6387328.2361126.51380June213615.513489.8270119.6387328.1366326.51380June213615.513489.8270119.6395728.7366326.51380June214915.413509.727.0<	September	2265	16.4	1343	9.7	2657	19.2	3766	27.2	3819	27.6	13849
December230516.013889.7277419.3398327.7391727.3143882022IIIIIIIIIIIJanuary224115.713929.7282219.7399027.9387127.014317February217415.8136810.0270419.7378027.5369826.913724March215315.913419.9262719.4376727.9363926.91357April215616.013389.9258619.2378228.0363927.01350March218715.613709.8271819.43774387328.2367326.913501June218715.613709.8271819.4376728.7363926.913501June218615.713479.8268519.6387328.2367126.71373June213615.513489.8270119.6387328.2367126.513806June213715.413699.7272319.6393928.3366326.513806June214315.413699.7272319.6393928.3366327.114058October219915.613899.7	October	2259	16.5	1323	9.7	2589	18.9	3739	27.3	3798	27.7	13709
2022Image: boot stateImage: boot sta	November	2273	16.5	1331	9.7	2612	19.0	3773	27.4	3770	27.4	13758
January224115.713929.7282219.7399027.9387127.014317February217415.8136810.0270419.7378027.5369826.913724March215315.913419.9262719.4376727.9363926.913527April215616.013389.9258619.2378228.0363927.013501May218715.613709.8271819.4397428.4374526.81395June215615.713479.8268519.6387328.2367126.71373June215615.713489.8270119.6395728.7363926.51380June213615.513489.8270119.6395728.7366326.51380August214315.413509.7272319.6393928.3375827.013913September217015.413699.7270419.2400828.5380727.114051November219915.613899.9273119.4395128.0382127.114051November219715.4139610.0268519.1395228.2382127.114051	December	2305	16.0	1388	9.7	2774	19.3	3983	27.7	3917	27.3	14368
February217415.8136810.0270419.7378027.5369826.913724March215315.913419.9262719.4376727.9363926.913527April215616.013389.9258619.2378228.0363927.013501May218715.613709.8271819.4397428.4374526.813995June215615.713479.8268519.6387328.2367126.71373Juny213615.713479.8270119.6395728.7366326.513806Juny213615.513489.8270119.6395728.7366326.513806August214315.413509.7272319.6395728.3375827.013913September217015.413699.7270419.2400828.5380727.114058October219915.613899.9273119.4395128.0382127.114091November216715.4139610.0268519.1396228.2382127.214031	2022											
March215315.913419.9262719.4376727.9363926.91357April215616.013389.9258619.2378228.0363927.013501May218715.613709.8271819.4397428.4374526.813995June215615.713479.8268519.6387328.2367126.71373July213615.513489.8270119.6395728.7366326.513806August214315.413509.7272319.6393928.3375827.013913September217015.413699.7270419.2400828.5380727.114058October219915.613899.9273119.4395128.0382127.114051November216715.4139610.0268519.1396228.2382127.114051	January	2241	15.7	1392	9.7	2822	19.7	3990	27.9	3871	27.0	14317
April215616.013389.9258619.2378228.0363927.013501May218715.613709.8271819.4397428.4374526.813995June215615.713479.8268519.6387328.2367126.713733July213615.513489.8270119.6395728.7366326.513806August214315.413509.7272319.6393928.3375827.013913September217015.413699.7270419.2400828.5380727.114058October219915.613899.9273119.4395128.2382127.114051November216715.4139610.0268519.1396228.2382127.214031	February	2174	15.8	1368	10.0	2704	19.7	3780	27.5	3698	26.9	13724
May218715.613709.8271819.4397428.4374526.81395June215615.713479.8268519.6387328.2367126.71373July213615.513489.8270119.6395728.7366326.513806August214315.413509.7272319.6393928.3375827.013913September217015.413699.7270419.2400828.5380727.114058October219915.613899.9273119.4395128.0382127.114091November216715.4139610.0268519.1396228.2382127.214031	March	2153	15.9	1341	9.9	2627	19.4	3767	27.9	3639	26.9	13527
June215615.713479.8268519.6387328.2367126.71373July213615.513489.8270119.6395728.7366326.513806August214315.413509.7272319.6393928.3375827.013913September217015.413699.7270419.2400828.5380727.114058October219915.613899.9273119.4395128.0382127.114091November216715.4139610.0268519.1396228.2382127.214031	April	2156	16.0	1338	9.9	2586	19.2	3782	28.0	3639	27.0	13501
July213615.513489.8270119.6395728.7366326.513806August214315.413509.7272319.6393928.3375827.013913September217015.413699.7270419.2400828.5380727.114058October219915.613899.9273119.4395128.0382127.114091November216715.4139610.0268519.1396228.2382127.214031	May	2187	15.6	1370	9.8	2718	19.4	3974	28.4	3745	26.8	13995
August214315.413509.7272319.6393928.3375827.013913September217015.413699.7270419.2400828.5380727.114058October219915.613899.9273119.4395128.0382127.114091November216715.4139610.0268519.1396228.2382127.214031	June	2156	15.7	1347	9.8	2685	19.6	3873	28.2	3671	26.7	13733
September      2170      15.4      1369      9.7      2704      19.2      4008      28.5      3807      27.1      14058        October      2199      15.6      1389      9.9      2731      19.4      3951      28.0      3821      27.1      14058        November      2167      15.4      1396      10.0      2685      19.1      3962      28.2      3821      27.2      14031	July	2136	15.5	1348	9.8	2701	19.6	3957	28.7	3663	26.5	13806
October      2199      15.6      1389      9.9      2731      19.4      3951      28.0      3821      27.1      14091        November      2167      15.4      1396      10.0      2685      19.1      3962      28.2      3821      27.2      14031	August	2143	15.4	1350	9.7	2723	19.6	3939	28.3	3758	27.0	13913
November      2167      15.4      1396      10.0      2685      19.1      3962      28.2      3821      27.2      14031	September	2170	15.4	1369	9.7	2704	19.2	4008	28.5	3807	27.1	14058
	October	2199	15.6	1389	9.9	2731	19.4	3951	28.0	3821	27.1	14091
December      2208      15.6      1421      10.0      2697      19.0      4018      28.4      3826      27.0      14169	November	2167	15.4	1396	10.0	2685	19.1	3962	28.2	3821	27.2	14031
	December	2208	15.6	1421	10.0	2697	19.0	4018	28.4	3826	27.0	14169

IRSAD: Index of Relative Socioeconomic Advantage and Disadvantage

\*Australia Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016. ABS: Canberra; 2018.





## Table A5. Estimated OAT clients per month by setting (VIC, 2013-2022)

Time period	Commu Pharm		Hospi	tal	Clinics a Medical Co		Other ( priso		Aged a Commu Health	unity
	n	Row %	n	Row %	n	Row %	n	Row %	n	Row %
2013										
January	8700	94.3	380	4.1	<5		144	1.6		
February	8388	94.1	395	4.4	<5		131	1.5		
March	8524	94.4	374	4.1			128	1.4		
April	8539	94.0	401	4.4	<5		138	1.5		
May	8968	94.3	391	4.1	<5		145	1.5		
June	8785	94.0	408	4.4	<5		154	1.6		
July	9054	94.5	371	3.9	<5		154	1.6		
August	9174	94.2	408	4.2	<5		157	1.6		
September	9573	94.6	386	3.8	5	0.1	156	1.5		
October	9808	94.2	442	4.2	5	0.1	152	1.5		
November	9831	94.7	391	3.8	<5		157	1.5		
December	10193	94.0	488	4.5	<5		160	1.5		
2014										
January	9973	93.9	481	4.5	<5		163	1.5		
February	9769	93.9	476	4.6	<5		156	1.5		
March	9581	94.2	422	4.1	5	0.0	166	1.6		
April	9788	94.3	430	4.1			162	1.6		
May	10099	93.9	477	4.4	6	0.1	172	1.6		
June	10026	94.0	474	4.4	6	0.1	160	1.5		
July	10154	93.9	479	4.4	6	0.1	176	1.6		
August	10130	94.0	459	4.3	6	0.1	180	1.7		
September	10265	93.9	470	4.3	6	0.1	190	1.7		
October	10374	94.3	444	4.0	5	0.0	182	1.7		
November	10108	94.1	450	4.2	5	0.0	182	1.7		
December	10558	94.1	472	4.2	6	0.1	185	1.7		
2015										
January	10098	94.2	440	4.1	6	0.1	182	1.7		
February	10057	94.4	407	3.8	6	0.1	182	1.7		
March	9726	94.6	361	3.5	4	0.0	192	1.9		
April	9852	94.6	377	3.6	5	0.0	184	1.8		
May	10155	94.5	400	3.7	6	0.1	188	1.7		





									Aged	and
Time period	Commu Pharma		Hospit	tal	Clinics a Medical C		Other ( priso		Commu Health	unity
	n	Row %	n	Row %	n	Row %	n	Row %	n	Row %
June	10007	94.7	385	3.6	6	0.1	167	1.6		
July	10206	94.8	383	3.6	7	0.1	172	1.6		
August	10249	95.1	360	3.3	6	0.1	162	1.5		
September	10278	95.1	353	3.3	7	0.1	170	1.6		
October	10264	95.4	339	3.2	7	0.1	154	1.4		
November	10113	95.3	339	3.2	8	0.1	151	1.4		
December	10388	95.0	381	3.5	6	0.1	158	1.4		
2016										
January	9944	95.0	354	3.4	9	0.1	155	1.5		
February	10051	95.1	355	3.4	9	0.1	153	1.4		
March	9869	95.6	310	3.0	10	0.1	140	1.4		
April	10045	95.5	319	3.0	9	0.1	142	1.3		
May	10099	95.6	311	2.9	9	0.1	148	1.4		
June	9955	95.4	336	3.2	10	0.1	133	1.3		
July	10086	95.4	335	3.2	11	0.1	145	1.4		
August	10220	95.4	337	3.2	13	0.1	140	1.3		
September	10186	95.6	315	3.0	13	0.1	145	1.4		
October	10188	95.5	319	3.0	9	0.1	149	1.4		
November	10009	95.7	292	2.8	7	0.1	150	1.4		
December	10451	95.8	288	2.6	6	0.1	158	1.5		
2017										
January	10314	96.0	283	2.6	6	0.1	143	1.3		
February	10067	95.5	322	3.1	8	0.1	144	1.4		
March	9880	95.5	330	3.2	8	0.1	124	1.2		
April	9926	95.7	307	3.0	8	0.1	136	1.3		
May	10366	95.8	299	2.8	9	0.1	143	1.3		
June	10372	95.7	304	2.8	9	0.1	149	1.4		
July	10609	95.7	316	2.9	12	0.1	152	1.4		
August	10658	95.6	343	3.1	11	0.1	139	1.2		
September	10589	95.7	322	2.9	10	0.1	144	1.3		
October	10707	95.7	338	3.0	9	0.1	135	1.2		
November	10750	95.5	347	3.1	7	0.1	149	1.3		
December	10924	95.4	366	3.2	9	0.1	147	1.3		





Time period	Commu Pharma		Hospit	tal	Clinics a Medical C		Other ( priso		Aged : Commu Health	unity
	n	Row %	n	Row %	n	Row %	n	Row %	n	Row %
2018										
January	10856	95.3	371	3.3	12	0.1	151	1.3		
February	10533	95.9	319	2.9	13	0.1	123	1.1		
March	10724	95.9	325	2.9	14	0.1	118	1.1		
April	10542	95.9	331	3.0	11	0.1	111	1.0		
May	10993	95.6	376	3.3	10	0.1	118	1.0		
June	10756	95.6	370	3.3	10	0.1	119	1.1		
July	11090	95.6	373	3.2	10	0.1	128	1.1		
August	11155	95.7	360	3.1	13	0.1	124	1.1		
September	10890	95.9	338	3.0	12	0.1	116	1.0		
October	11078	96.2	325	2.8	12	0.1	97	0.8		
November	10945	96.2	341	3.0	14	0.1	82	0.7		
December	11432	96.0	375	3.1	11	0.1	85	0.7		
2019										
January	11166	96.0	364	3.1	14	0.1	84	0.7		
February	10887	96.0	346	3.1	8	0.1	95	0.8		
March	10673	96.1	337	3.0	7	0.1	85	0.8		
April	10777	95.8	378	3.4			88	0.8		
May	11296	96.0	375	3.2			98	0.8		
June	11194	95.9	386	3.3	<5		94	0.8		
July	11385	95.9	374	3.2			109	0.9		
August	11278	96.1	365	3.1			98	0.8		
September	11369	96.0	365	3.1	<5		108	0.9	11	0.1
October	11402	95.9	373	3.1			99	0.8	27	0.2
November	11345	95.2	428	3.6	<5		103	0.9	38	0.3
December	11776	94.8	447	3.6	5	0.0	118	0.9	77	0.6
2020										
January	11456	94.3	476	3.9	11	0.1	122	1.0	80	0.7
February	11245	94.1	477	4.0	25	0.2	117	1.0	89	0.7
March	11876	93.7	528	4.2	55	0.4	136	1.1	85	0.7
April	11582	93.0	563	4.5	94	0.8	115	0.9	103	0.8
May	11771	92.9	531	4.2	138	1.1	120	0.9	111	0.9
June	11089	92.2	522	4.3	190	1.6	111	0.9	120	1.0





Time newled	Commu	nity	Unani		Clinics a	and	Other (	incl.	Aged a	
Time period	Pharma	асу	Hospi	al	Medical C	entres	priso	ns)	Commu Health	
	n	Row %	n	Row %	n	Row %	n	Row %	n	Row %
July	11886	92.2	518	4.0	229	1.8	116	0.9	147	1.1
August	12198	91.5	565	4.2	280	2.1	130	1.0	153	1.1
September	12354	91.5	562	4.2	315	2.3	111	0.8	167	1.2
October	12518	91.0	598	4.3	370	2.7	120	0.9	153	1.1
November	12488	90.6	634	4.6	345	2.5	117	0.8	193	1.4
December	12886	90.5	679	4.8	333	2.3	122	0.9	213	1.5
2021										
January	12265	90.6	629	4.6	303	2.2	127	0.9	212	1.6
February	11963	90.4	619	4.7	361	2.7	117	0.9	178	1.3
March	11805	90.1	620	4.7	378	2.9	126	1.0	177	1.4
April	11996	90.3	639	4.8	367	2.8	117	0.9	172	1.3
May	12168	89.8	648	4.8	389	2.9	126	0.9	216	1.6
June	11732	89.5	649	4.9	421	3.2	107	0.8	203	1.5
July	12017	88.9	660	4.9	487	3.6	103	0.8	243	1.8
August	12245	88.7	740	5.4	498	3.6	78	0.6	247	1.8
September	12299	88.8	700	5.1	525	3.8	73	0.5	252	1.8
October	12133	88.5	728	5.3	529	3.9	68	0.5	251	1.8
November	12172	88.5	699	5.1	576	4.2	72	0.5	239	1.7
December	12673	88.2	741	5.2	630	4.4	73	0.5	252	1.8
2022										
January	12519	87.4	712	5.0	754	5.3	73	0.5	259	1.8
February	11920	86.9	684	5.0	797	5.8	73	0.5	250	1.8
March	11608	85.8	697	5.2	902	6.7	63	0.5	257	1.9
April	11674	86.5	727	5.4	796	5.9	58	0.4	246	1.8
May	12015	85.9	767	5.5	868	6.2	55	0.4	291	2.1
June	11799	85.9	771	5.6	808	5.9	60	0.4	295	2.1
July	11778	85.3	785	5.7	874	6.3	61	0.4	307	2.2
August	11926	85.7	797	5.7	836	6.0	56	0.4	299	2.1
September	12017	85.5	835	5.9	841	6.0	53	0.4	312	2.2
October	11987	85.1	855	6.1	884	6.3	52	0.4	313	2.2
November	11840	84.4	901	6.4	925	6.6	56	0.4	309	2.2
December	12033	84.9	914	6.4	860	6.1	62	0.4	300	2.1





Time period	Com	munity Pha	armacy		Hospita	ı	Clinics	& Medica	l Centres
period	LAI bup	SL bup	Methadone	LAI bup	SL bup	Methadone	LAI bup	SL bup	Methadone
	n	n	n	n	n	n	n	n	n
2013									
January		1797	6904		17	363		<5	
February		1749	6639		20	375		<5	
March		1787	6738		21	353			
April		1862	6677		23	378		<5	
May		1991	6977		21	369		<5	
June		2023	6762		23	385		<5	
July		2126	6927		23	348		<5	
August		2274	6900		26	382		<5	
September		2538	7035		27	359		5	
October		2785	7023		31	411		5	
November		2922	6908		34	357		<5	
December		3110	7083		46	441		<5	
2014									
January		3051	6921		57	424		<5	
February		3006	6763		63	413		<5	
March		2920	6661		59	363		5	
April		3049	6739		56	374			
May		3158	6941		58	419		6	
June		3161	6864		65	409		6	
July		3156	6998		70	409		6	
August		3163	6967		65	394		6	
September		3178	7086		67	403		6	
October		3241	7134		70	375		5	
November		3156	6952		78	373		5	
December		3363	7195		77	395		6	
2015									
January		3223	6875		73	367		6	
February		3233	6824		66	341		6	
March		3102	6624		70	291		<5	
April		3163	6689		70	307		5	
May		3261	6894		79	322		6	





Time	Com	munity Ph	armacy		Hospital Clinics & Medical Centres					
period	LAI bup	SL bup	Methadone	LAI bup	SL bup	Methadone	LAI bup	SL bup	Methadone	
	n	n	n	n	n	n	n	n	n	
June		3214	6793		71	314		6		
July		3287	6919		74	309		6	<5	
August		3323	6926		68	292		5		
September		3372	6905		69	284		6		
October		3351	6913		66	274		7		
November		3298	6814		67	272		8		
December		3412	6976		74	307		6		
2016										
January		3265	6679		71	282		9		
February		3279	6772		76	278		9		
March		3253	6616		69	241		10		
April		3296	6749		70	249		9		
May		3360	6739		60	251		9		
June		3271	6684		69	268		9	<5	
July		3359	6727		67	268		11		
August		3381	6838		74	263		12		
September		3337	6850		68	247		13		
October		3373	6815		67	253		9		
November		3332	6676		64	227		7		
December		3590	6861		56	232		6		
2017										
January		3517	6797		57	226		6		
February		3439	6629		59	263		8		
March		3314	6566		71	259		8		
April		3387	6539		70	237		8		
May		3544	6823		79	220		9		
June		3597	6775		77	227		9		
July		3656	6953		83	233		12		
August		3685	6973		70	272		11		
September		3628	6961		64	258		10		
October		3690	7017		64	274		9		
November		3722	7028		66	281		7		
December		3828	7096		73	294		9		
2018										





Time	Com	munity Ph	armacy		Hospital Clinics & Medical Centres					
period	LAI bup	SL bup	Methadone	LAI bup	SL bup	Methadone	LAI bup	SL bup	Methadone	
	n	n	n	n	n	n	n	n	n	
January		3818	7037		70	301		12		
February		3720	6813		74	246		13		
March		3783	6940		78	246		14		
April		3751	6790		81	250		11		
May		3924	7070		87	289		10		
June		3858	6898		78	292		10		
July		3967	7123		79	294		10		
August		4013	7142		71	289		13		
September		3951	6939		70	267		12		
October		4057	7021		75	250		12		
November		4031	6914		79	262		14		
December		4219	7213		81	294		11		
2019										
January		4108	7058		74	290		14		
February		4016	6871		69	277		8		
March		3928	6746		67	270		7		
April		3965	6812		65	313				
May		4266	7030		71	304				
June		4225	6969		71	314		<5		
July		4317	7068		75	299				
August		4187	7091		66	300				
September	7	4253	7114	18	62	298		<5		
October	11	4270	7125	39	65	282				
November	17	4264	7065	67	69	292	<5			
December	22	4393	7362	88	71	288	6			
2020										
January	29	4245	7182	107	64	305	11			
February	32	4192	7021	115	63	299	25			
March	80	4319	7477	172	72	284	55			
April	104	4244	7233	200	76	287	94			
May	158	4233	7380	190	74	267	138			
June	217	3983	6889	207	63	253	190		<5	
July	316	4155	7415	228	64	226	229		<5	
August	425	4156	7617	262	61	243	280			





Time	Com	munity Ph	armacy		Hospital Clinics & Medical Centres					
period	LAI bup	SL bup	Methadone	LAI bup	SL bup	Methadone	LAI bup	SL bup	Methadone	
	n	n	n	n	n	n	n	n	n	
September	499	4152	7704	260	61	241	315			
October	590	4113	7815	280	55	264	370			
November	672	4025	7792	310	62	263	345			
December	771	4130	7985	336	72	270	333			
2021										
January	755	3948	7562	328	72	228	303			
February	736	3831	7396	331	65	222	361			
March	804	3727	7274	328	50	242	378			
April	853	3752	7392	336	48	255	367			
May	905	3812	7451	335	53	260	389			
June	874	3689	7169	357	52	239	421			
July	950	3803	7264	382	57	221	487			
August	1068	3841	7336	437	61	242	498			
September	1107	3850	7343	418	66	215	525			
October	1129	3751	7253	428	63	237	529			
November	1144	3691	7337	440	54	206	576			
December	1321	3816	7536	451	55	234	629	<5		
2022										
January	1427	3687	7404	463	50	200	754			
February	1439	3555	6926	449	48	187	796			
March	1504	3400	6704	482	42	173	902			
April	1465	3475	6734	482	46	199	795	<5		
May	1576	3556	6883	521	48	198	867			
June	1463	3515	6821	523	48	200	808			
July	1545	3493	6740	534	51	201	874			
August	1541	3534	6850	567	51	178	835		<5	
September	1602	3516	6899	604	55	176	840			
October	1615	3450	6923	644	59	152	883	<5		
November	1667	3402	6772	668	59	174	925	<5		
December	1753	3458	6822	689	58	166	860	<5		



## 7. References

1. World Health Organization, Department of Mental Health and Substance Abuse. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009.

2. Colledge-Frisby S, Jones N, Larney S, et al. The impact of opioid agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent population: A retrospective data linkage study. *Drug and Alcohol Dependence* 2022; **236**: 109494.

3. Degenhardt L, Grebely J, Stone J, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. *Lancet* 2019; **394**(10208): 1560-79.

4. Gisev N, Bharat C, Larney S, et al. The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. *Lancet Public Health* 2019; **4**(7): e334-e42.

5. Santo T, Jr., Clark B, Hickman M, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. *JAMA Psychiatry* 2021; **78**(9): 979-93.

6. World Health Organization. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users–2012 revision. 2012.

7. Colledge-Frisby S, Ottaviano S, Webb P, et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. *Lancet Global Health* 2023; **11**(5): e673-e83.

8. World Health Organization. WHO Model List of Essential Medicines. World Health Organization; 2017.

9. Australian Government Department of Health and Aged Care. The Pharmaceutical Benefits Scheme (PBS). 2023. <u>https://www.pbs.gov.au/pbs/home</u> (accessed 21 June 2023).

10. Lintzeris N, Dunlop A, Masters D. Clinical Guidelines for Use of Depot Buprenorphine (Buvidal and Sublocade) in the Treatment of Opioid Dependence: NSW Ministry of Health; 2019.

11. Australian Product Information: Buvidal<sup>®</sup> weekly (buprenorphine) solution for injection. Therapeutic Goods Administration, 2018.

12. Australian Product Information: Buvidal<sup>®</sup> monthly (buprenorphine) solution for injection. Therapeutic Goods Administration, 2018.

13. Australian Product Information: Sublocade (Buprenorphine). Therapeutic Goods Administration, 2019.

14. Frost M, Bailey GL, Lintzeris N, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. *Addiction* 2019; **114**(8): 1416-26.

15. Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2019; **393**(10173): 778-90.



16. Farrell M, Shahbazi J, Byrne M, et al. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. *International Journal of Drug Policy* 2022; **100**: 103492.

17. Barnett A, Savic M, Lintzeris N, et al. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. *Drug and Alcohol Dependence* 2021; **227**: 108959.

18. Clay S, Treloar C, Degenhardt L, et al. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue. *International Journal of Drug Policy* 2023; **115**: 104002.

19. Lancaster K, Gendera S, Treloar C, et al. The Social, Material, and Temporal Effects of Monthly Extended-Release Buprenorphine Depot Treatment for Opioid Dependence: An Australian Qualitative Study. *Contemporary Drug Problems* 2023; **50**(1): 105-20.

20. Lintzeris N, Hayes V, Arunogiri S. Interim guidance for the delivery of medication assisted treatment of opioid dependence in response to COVID <sup>-</sup> 19: a national response. Royal Australasian College of Physicians, 2020.

21. Hall NY, Le L, Majmudar I, Mihalopoulos C. Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective. *Drug and Alcohol Dependence* 2021; **221**: 108651.

22. Victorian Government Department of Health. SafeScript. 14 July 2023 2019. <u>https://www.health.vic.gov.au/drugs-and-poisons/for-prescribers-and-pharmacists</u> (accessed 20 July 2023.

23. Australian Institute of Health Welfare. National Opioid Pharmacotherapy Statistics Annual Data collection. Canberra: AIHW, 2023.

24. IQVIA Australia & New Zealand. Navigating COVID-19 Impact: An initial assessment of the pandemic's effect on Australian healthcare. *White paper series - Part 1*, 2020.

https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/iqvia-anz-covid-19 white-paper.pdf (accessed 20 July 2023).

25. Australian Government Department of Health and Aged Care. Post-market Review of PBS Opioid Dependence Treatment Program medicines: Interim Report to the Pharmaceutical Benefits Advisory Committee. Canberra, 2023.

26. Pharmaceutical Benefits Advisory Committee. Positive Recommendations made by the PBAC in March 2001. Canberra: Australian Government Department of Health and Aged Care; 2001.

27. Pharmaceutical Benefits Advisory Committee. Positive Recommendations made by the PBAC November 2005. Canberra: Australian Government Department of Health and Aged Care; 2005.

28. Pharmaceutical Benefits Advisory Committee. Positive Recommendations made by the PBAC March 2011. Canberra: Australian Government Department of Health and Aged Care; 2011.

29. Chidwick K, Bharat C, Gisev N, Farrell M, Degenhardt L. NDARC Technical Report: Realworld dosing intervals of long-acting buprenorphine for opioid agonist treatment. Sydney: UNSW, 2023.



 Reece AS, Norman A, Hulse GK. Acceleration of cardiovascular-biological age by amphetamine exposure is a power function of chronological age. *Heart Asia* 2017; 9(1): 30-8.
 Valerio H, Alavi M, Silk D, et al. Progress Towards Elimination of Hepatitis C Infection

Among People Who Inject Drugs in Australia: The ETHOS Engage Study. *Clinical Infectious Diseases* 2021; **73**(1): e69-e78.

32. Haber PS, Elsayed M, Espinoza D, Lintzeris N, Veillard AS, Hallinan R. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. *Drug and Alcohol Dependence* 2017; **181**: 132-9.

33. Kelty E, Hulse G. Rates of Hospital and Emergency Department Attendances in Opiatedependent Patients Treated With Implant Naltrexone, Methadone, or Buprenorphine. *Addictive Disorders & Their Treatment* 2017; **16**(2): 39-48.

34. Larance B, Degenhardt L, Grebely J, et al. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. *Addiction* 2020; **115**(7): 1295-305.

35. Larney S, Lai W, Dolan K, Zador D. Monitoring a Prison Opioid Treatment Program Over a Period of Change to Clinical Governance Arrangements, 2007-2013. *Journal of Substance Abuse Treatment* 2016; **70**: 58-63.

36. Jamshidi N, Athavale A, Murnion B. Buprenorphine not detected on urine drug screening in supervised treatment. *Journal of Opioid Management* 2021; **17**(7): 69-76.

37. Australian Bureau of Statistics. Australian Statistical Geography Standard (ASGS): Volume 5 - Remoteness Structure, July 2016 ABS: Canberra; 2018.

38. Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016. ABS: Canberra; 2018.

39. Australian Bureau of Statistics. National, state and territory population, September 2022. Canberra: ABS; 2023.

40. Bharat C, Larney S, Barbieri S, et al. The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. *Addiction* 2021; **116**(11): 3139-52.

41. Straub A, Pastor A, Lloyd-Jones M, O'Neill H, Bonomo Y. The development and implementation of a rapid-access long-acting injectable buprenorphine clinic in metropolitan Melbourne during the COVID-19 pandemic. *Drug and Alcohol Review* 2021; **40**(4): 681-2.